Skip to content

The Safety and Efficacy of Microneedle Patch for Ameliorating Dry Skin in Atopic Dermatitis

The Safety and Efficacy of Soluble Microneedle Drug Delivery System Combined with Korean Medicine for Ameliorating Dry Skin in Atopic Dermatitis: An Investigator-initiated, Assessor-blinded, Randomized controlled Parallel Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0005942
Enrollment
20
Registered
2021-03-02
Start date
2020-12-28
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Microneedle patch used in this study is a medical device made up of biodegradable hyaluronic acid microneedles on the hydrocolloid substrate film. If the patch is attached after apply

Sponsors

Naju Dongshin University Korean Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Male and female patients aged 19-60 at the screening visit. (2) Atopic dermatitis patients diagnosed by Hanifin and Rajka criteria and have dry skin. Atopic dermatitis can be diagnosed if the patient has more than 3 of 4 major symptoms and 3 of 23 minor symptoms in the Hanifin and Rajka criteria. (3) Patients who have 2 similar dry areas at the limbs in order to compare the efficacy of solitary local external preparation application with combination therapy of local application and soluble microneedle patch. (4) Patients who submitted written consent voluntarily.

Exclusion criteria

Exclusion criteria: (1) Patients who were taking intensive medication such as antihistamines or steroids. (2) Patients who used oral antihistamines, oral antibiotics, oral or topical steroids, systemic photochemotherapy, or other immunosuppressants within 4 weeks before this study begins. (3) Patients having systemic infection or taking systemic antibiotic therapy. (4) Patients having other severe skin diseases except atopic dermatitis. (5) Patients taking interferon medication. (6) Liver patients including cirrhosis or liver cancer. (7) Kidney patients including acute or chronic renal failure, or nephrotic syndrome. (8) Severe acute cardiovascular patients including heart failure, myocardial infarction, or stroke. (9) Patients who took antipsychotics within 3 months before screening. (10) Patient who are sensitive to natural products. (11) Patients who have an allergy to adhesives. (12) Pregnant or nursing women. (13) Severe oozing or maceration. (14) Others who investigators decided inadequate.

Design outcomes

Primary

MeasureTime frame
Change in skin lesion comparing photos on the 2nd week with the baseline;Change in L-SCORAD index on the 2nd week from the baseline

Secondary

MeasureTime frame
Change in investigator's global assessment(IGA) score on the 2nd week from the baseline;Change in total SCORAD index on the 2nd week from the baseline;Change in DLQI score on the 2nd week from the baseline;Change in VAS score for pruritus on the 2nd week from the baseline;Change in VAS score for skin dryness on the 2nd week from the baseline;Change in skin hydration on the 2nd week from the baseline;Change in transepidermal water loss(TEWL) on the 2nd week from the baseline;Change in participant's satisfaction on the 2nd week from the baseline

Countries

Korea, Republic of

Contacts

Public ContactJi-Hoon Song

Dongshin University

kmdsjh0122@nate.com+82-61-338-7811

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026